Lupus has high unmet needs and a very active pipeline, including AstraZeneca’s anifrolumab, Eli Lilly’s Olumiant, novel TYK-2 inhibitors from...
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains...
The firm, which was recently recognized by Philadelphia Business Journal as one of the area’s Soaring 76 fastest growing companies...
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing...
Spherix Global Insights releases fifth annual patient chart study focused exclusively on biologic and small molecule switching patterns among US...
A stark contrast in use and preference of the JAK inhibitors between the two regions sets varying competitive landscapes for...
A new independent study conducted by Spherix Global Insights reveals projected erosion of branded TNF inhibitors and stabilization of biosimilars...
The newest market entrant and possibly next autoimmune blockbuster has had an impressive launch so far, according to Spherix Global...
According to feedback from the sixth wave of COVID-19 impact tracking, Spherix Global Insights finds that patient volumes remain severely...
From: Ankylosing Spondylitis News By: Patricia Inacio, PhD. According to Spherix Global Insights’ survey, which was...
In AS, the IL-17 inhibitors are beginning to challenge the leading TNF inhibitors, but rheumatologists struggle to differentiate Novartis’ Cosentyx...
The impact to practices has been severely disruptive, taking a devastating personal and financial toll on specialty physicians according to...
